Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab

Leukemia & Lymphoma
M E O'DwyerC R Nichols

Abstract

A 52 year -old female developed a histologically aggressive, Epstein-Barr virus positive, lymphoproliferative disorder involving the brain and liver 4 months following a combined kidney/pancreas transplant. Following a brief trial of reduced immunosuppression, she was treated with rituximab. Despite subsequent re-intensification of immunosuppression, the lesions showed continued regression with almost complete disappearance by 5 months. Rituximab appears to be a safe, effective treatment for post transplant lymphoproliferative disorder.

Citations

Dec 20, 2002·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Jean HermanRita Van Damme-Lombaerts
Jun 7, 2002·Journal of Pediatric Gastroenterology and Nutrition·Françoise Smets, Etienne M Sokal
Sep 1, 2005·Journal of Pediatric Gastroenterology and Nutrition·Anita TalisettiEnrico Benedetti
Sep 24, 2005·Transplantation·Steven ParaskevasRainer W G Gruessner
Oct 12, 2007·Paediatric Drugs·Asha Moudgil, Dechu Puliyanda
Dec 18, 2007·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Y-C HsuJ-T Lin
Jun 13, 2009·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·N IssaM D Griffin
Mar 3, 2009·Journal of Pediatric Gastroenterology and Nutrition·B R LuM R Narkewicz

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.